June 16, 2024 - Bay Street News

NASDAQ Companies - June 16, 2024

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating […]

NASDAQ Companies - June 16, 2024

Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma

At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% […]

NASDAQ Companies - June 16, 2024

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses […]

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search